Table 1.
Percentage variation in chamber measured dose from calculated phase dose for the tumor position in each phase of the 4DCT dataset
| Tumor chamber dose | Dose variation from planned | |||||
|---|---|---|---|---|---|---|
| Inferior 2 cm | Inferior 1 cm | Plan geometry | Superior 1 cm | Superior 2 cm | Average variation | |
| 10 × 10 | −1.9% | −0.7% | −0.7% | −0.8% | −2.3% | −1.3% |
| GTV | 5.1% | 1.0% | 0.5% | 2.2% | 3.7% | 2.5% |
| ITV | −0.5% | 1.9% | 0.9% | 1.9% | 0.8% | 1.0% |
| Average | −3.3% | −3.2% | −3.0% | 1.5% | 0.8% | −1.4% |
| Lung override | −5.7% | −1.7% | −1.8% | 0.9% | 1.0% | −1.4% |
| Robust all | −1.2% | −0.2% | 1.8% | −0.1% | −0.3% | 0.0% |
| Robust extremes | 2.4% | −1.0% | −2.4% | −0.9% | 0.8% | −0.2% |
| Robust values | −0.5% | 1.4% | 0.5% | 0.0% | −0.1% | 0.2% |
| Average variation | −0.7% | −0.3% | −0.5% | 0.6% | 0.5% | |
| Standard deviation | 3.3% | 1.7% | 1.7% | 1.2% | 1.7% | |